Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 10.75 3.07% 0.32
SNDX closed up 3.57 percent on Wednesday, February 19, 2020, on 1.35 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 5
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SNDX trend table...

Date Alert Name Type % Chg
New Uptrend Bullish 3.07%
Stochastic Reached Overbought Strength 3.07%
Wide Bands Range Expansion 3.07%
Gapped Up Strength 3.07%
Overbought Stochastic Strength 3.07%
Pocket Pivot Bullish Swing Setup 6.75%
Volume Surge Other 6.75%
Multiple of Ten Bullish Other 6.75%
Wide Bands Range Expansion 6.75%
Doji - Bearish? Reversal 12.33%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Pyridines Lung Cancer Late Stage Biopharmaceutical Hematological Malignancies Benzamides Carbamates Draft:Syndax National Cancer Institute

Is SNDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.11
52 Week Low 4.52
Average Volume 158,095
200-Day Moving Average 8.25
50-Day Moving Average 8.75
20-Day Moving Average 8.83
10-Day Moving Average 9.73
Average True Range 0.69
ADX 25.41
+DI 32.29
-DI 13.75
Chandelier Exit (Long, 3 ATRs ) 8.84
Chandelier Exit (Short, 3 ATRs ) 8.39
Upper Bollinger Band 11.49
Lower Bollinger Band 6.16
Percent B (%b) 0.8
BandWidth 60.39
MACD Line 0.45
MACD Signal Line 0.33
MACD Histogram 0.1259
Fundamentals Value
Market Cap 231.74 Million
Num Shares 22.2 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -3.67
Price-to-Sales 191.23
Price-to-Book 2.13
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.38
Resistance 3 (R3) 11.39 11.08 11.22
Resistance 2 (R2) 11.08 10.84 11.08 11.16
Resistance 1 (R1) 10.76 10.69 10.92 10.75 11.11
Pivot Point 10.45 10.45 10.54 10.45 10.45
Support 1 (S1) 10.13 10.21 10.29 10.12 9.75
Support 2 (S2) 9.82 10.06 9.82 9.70
Support 3 (S3) 9.50 9.82 9.64
Support 4 (S4) 9.49